Schering AG and Stanford University began a joint research program to develop molecular imaging agents for the diagnosis and follow-up of cancer. Specifically, the cooperation will focus on the identification of novel positron emission tomography (PET) tracers for tumor imaging.
Under the terms of the agreement, Schering will have the option to assume exclusive rights for the development and commercialization of such tracers.
Molecular imaging allows early diagnoses of pathological changes in the body at the molecular level, even before they can be diagnosed using other imaging procedures. Such methods should allow the very early and precise detection and characterization of cancer and other diseases, such as those of the central nervous system.
Schering has already established several research collaborations in the field of molecular imaging. Collaboration partners include Avid Radiopharmaceuticals as well as the Swiss Federal Institute of Technology.